Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...

Domino's Pizza -- one of the best performing stocks of the last two decades -- headlines Monday's slate of earnings. Hims & Hers Health -- [whose shares tumbled Friday after Novo Nordisk said a shorta ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...

US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses: Plainsboro, New Jersey Monday, February 24, ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.